

available at [www.sciencedirect.com](http://www.sciencedirect.com)  
journal homepage: [www.europeanurology.com](http://www.europeanurology.com)



## Corrigendum

# Corrigendum re “Neoadjuvant Short-term Intensive Intravesical Mitomycin C Regimen Compared with Weekly Schedule for Low-grade Recurrent Non-muscle-invasive Bladder Cancer: Preliminary Results of a Randomised Phase 2 Study” [Eur Urol 2012;62:797–802]

Renzo Colombo<sup>a,b</sup>, Lorenzo Rocchini<sup>a,b,\*</sup>, Nazareno Suardi<sup>a,b</sup>, Fabio Benigni<sup>b</sup>, Giorgia Colciago<sup>b</sup>, Arianna Bettiga<sup>b</sup>, Federico Pellucchi<sup>a,b</sup>, Carmen Maccagnano<sup>a,b</sup>, Alberto Briganti<sup>a,b</sup>, Andrea Salonia<sup>a,b</sup>, Patrizio Rigatti<sup>a,b</sup>, Francesco Montorsi<sup>a,b</sup>

<sup>a</sup> Department of Urology, University Vita-Salute, Milan, Italy; <sup>b</sup> Urological Research Institute, University Vita-Salute, Milan, Italy

It has been brought to our attention that for the secondary outcome of tumour response, we reported an incorrect *p* value of 0.04 for a  $\chi^2$  test comparing the groups. A careful reanalysis of all our results revealed that the *p* value is in fact 0.054 for this secondary outcome. However, we believe that given the low number of patients included in the study, a *p* value 0.054 instead of 0.04, which demonstrates borderline significance, does not invalidate the main study results.

**Conflicts of interest:** The authors have nothing to disclose.

DOI of original article: <https://doi.org/10.1016/j.eururo.2012.05.032>.

\* Corresponding author.

E-mail address: [lorenzo.rocchini@gmail.com](mailto:lorenzo.rocchini@gmail.com) (L. Rocchini).

<https://doi.org/10.1016/j.eururo.2018.09.012>

0302-2838/© 2018 European Association of Urology. Published by Elsevier B.V. All rights reserved.

